Atopic Dermatitis, Eczema
Conditions
Brief summary
The utility of functionally relevant signature genes in assessing the clinical outcomes of dupilumab treatment in the adult onset atopic dermatitis
Detailed description
The study consists of 9 visits. Duplimab will used in the treatment of adult onset atopic dermatitis. Qualified subjects will receive 5 dupilumab open-label injections. Skin biopsies/ skin strips will be obtained at the beginning and the end of treatment. TARC and IgE levels will be obtained at the beginning and end of treatment. Subjects will complete daily diaries assessing atopic dermatitis symptoms. Patient reported out comes will be completed at each visit
Interventions
BIOLOGICALDupilumab Prefilled Syringe
open-label
Sponsors
Jonathan A. Bernstein, MD
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* history of adult onset atopic dermatitis
Exclusion criteria
\-
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The primary objective of this study is to correlate cutaneous transcriptomes with before and after Dupilumab treatment outcomes in patients who meet the clinical diagnostic criteria for adult onset AD. | after 6 months | Data will be analyzed from skin punch biopsies from active skin lesions and uninvolved skin samples before and after treatment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| To investigate possible influence of Dupilumab on serologic protein biomarkers in patients with adult onset AD | after 6 months | Total IgE, TARC and eotaxin will be compared pre and post treatment |
Countries
United States
Outcome results
None listed